Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space.Oncology or cancer is one of the most sought-after areas in the pharma/biotech space....
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer drug prices are rising sharply, with Bloomberg reporting growing concern over affordability and...
Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.06%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.10%. June E-mini S&P futures (ESM25...
The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.84%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.00%. June E-mini...
Bristol Myers BMY is focused on developing drugs with presence in oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. BMY depends on label expansion of approved...
With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024...
Bristol Myers BMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint.Sotyktu is an oral, selective tyrosine kinase...
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END